Previous 10 | Next 10 |
2024-04-18 07:28:39 ET Summary On April 16, Johnson & Johnson released financial results for the first three months of 2024, which were within my expectations. Tecvayli sales were $133 million in the first quarter of 2024, up 111% year over year. Despite increased competit...
2024-04-17 10:24:12 ET Summary TG Therapeutics shares are down 60% from their 52-week high after rival MS therapy Ocrevus achieved non-inferiority as a subcutaneously injected therapy. Initial sales of TG Therapeutics' anti-CD20 MS treatment Briumvi were solid, generating $92 mill...
2024-04-17 09:30:00 ET Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its shareholders by constantly raising its payouts -- and if it can do so for long...
2024-04-17 09:26:31 ET More on CVS Health CVS Health: Seizing Opportunity Amid Recent Declines CVS Health: Good Management Is Keeping Their Promises CVS Health: Here Comes The Floor - Inherent Undervaluation Triggers Great Upside Potential Dividend Roundup: P...
2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) PR Newswire APPLAUSE-IgAN is first and only Phase III study to demonstrate significant...
2024-04-13 10:52:04 ET More on AbbVie, Amgen, etc. AbbVie: Bulletproof Fundamentals AbbVie: Despite The Run, Shares Still Look Attractive, Yielding 3.67% UnitedHealth Q1 2024 Earnings Preview: Headwinds Not Enough To Derail This Juggernaut GLP-1s benefit Park...
2024-04-11 15:50:52 ET Summary Arvinas' shares have experienced a significant increase, up more than 75% since November 2023, due to the success of its lead asset, vepdegestrant, in breast cancer studies. Arvinas entered into a strategic license agreement with Novartis for the dev...
2024-04-11 15:23:48 ET Summary Vertex Pharmaceuticals is acquiring Alpine Immune Sciences for $4.9 billion, gaining access to povetacicept, a potential treatment for IgA nephropathy and up to seven additional indications. Povetacicept has shown promising results in reducing protei...
2024-04-11 08:36:33 ET More on Alpine Immune Sciences Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug Vertex enters into agreement to acquire Alpine Immune Sciences ...
News, Short Squeeze, Breakout and More Instantly...
Novartis AG Company Name:
NVS Stock Symbol:
NYSE Market:
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a...
2024-05-14 06:30:00 ET There are many dividend stocks on the market. Some will eventually cut or suspend their payouts due to company-specific, economic, or broader market issues. Those aren't the kind of dividend stocks that investors will want to own. Instead, income-seekers should try to...
MacroGenics Inc (NASDAQ:MGNX) released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo). TAMARA...